Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

---

Atıf İçin Kopyala

Taşkın S., Gungor M. , Ortac F., Öztuna D.

Archives of gynecology and obstetrics, cilt.288, ss.1399-403, 2013 (SCI İndekslerine Giren Dergi)

• Cilt numarası: 288
• Basım Tarihi: 2013
• Doi Numarası: 10.1007/s00404-013-2924-7
• Dergi Adı: Archives of gynecology and obstetrics
• Sayfa Sayıları: ss.1399-403

Özet

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance